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 Abstract  
Objective: This study aimed to compare the relaxant properties of BRL 37344 with β
2
-adrenoceptors agonist 
ritodrine on the contractility of human nonpregnant myometrium. 
Material and methods: The activity of myometrial strips mounted in an organ bath was recorded under isometric 
conditions using force transducers with digital output. Contractility before and after cumulative additions of both 
uterorelaxants and with preincubation with β-adrenoceptor antagonists bupranolol, propranolol, and butoxamine 
were studied.  
Results: Both BRL 37344 (10-10 – 10-4 mol/L) and ritodrine (10-10 – 10-5 mol/L) decreased the area under curve, 
or AUC, value (logIC
50
 -6.45 ± 0.18 and -8.71 ± 0.35, respectively), and the degree of inhibition of spontaneous 
contractile activity was similar (< 30%). However, BRL 37344 decreased the mean frequency of contractions, 
whereas ritodrine decreased the mean amplitude of contractions. The inhibition of contractions by BRL 37344 
was partially antagonized by bupranolol and propranolol, but not with butoxamine. The inhibition by ritodrine was 
counteracted by all these antagonists.  
Conclusions: The effects of BRL37344 and ritodrine on human nonpregnant myometrium are quantitatively similar 
in respect to the inhibition of spontaneous contractility, yet are also distinct due to their substantially different 
influences on contraction parameters. Our data indicate that β
3
-adrenoceptor activation is not the sole effect of BRL 
37344 on this tissue.  
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Introduction 
Both	 receptors	 subclasses,	 β
2
-	 and	 β
3
-adrenoceptors	 have	
been	 shown	 to	mediate	 the	 contractile	 response	 of	 the	 human	
uterus.	 The	 regulation	 of	 the	 β-adrenoceptors	 in	 humans	 may	
vary	due	to	numerous	pharmacologic,	physiologic,	and	hormonal	
influences,	and	the	impact	of	the	phases	of	the	menstrual	cycle,	
pregnancy,	or	menopause	[1].	Furthermore,	the	β
3
-adrenoceptors	
have	been	characterized	and	their	functionality	shown	in	pregnant	
human	myometrium	[2,	3].	The	expression	of	β
3
-adrenoceptors	
increases	in	the	near-term	myometrium	[1].	Two	populations of	
binding	 sites	 corresponding	 to	 β
2
-	 and	 β
3
-adrenoceptors	 have	
been	 identified,	 and	 the	 predominance	 of	 the	 β
3
-adrenoceptors	
subtype	 in	 the	 nonpregnant	 and	 pregnant	 human	myometrium	
were	also	confirmed	[4].		
β
2
-Adrenoceptor	agonists,	such	as	ritodrine,	are	well-known	
drugs	 used	 for	 the	 management	 of	 preterm	 labor.	 However,	
maternal	 and	 fetal	 cardiovascular	 side	 effects	 restrict	 their	
limitations	 in	 clinical	 practice	 [5].	According	 to	 our	 previous	
study,	a	β
3
-adrenoceptors	agonist,	CL	316243,	efficiently	inhibits	
spontaneous	 contractions	 of	 human	 nonpregnant	 myometrium	
[6].	This	finding	is	parallel	to	the	Rouget	et al.	study,	in	which	
a	 β
3
-adrenoceptors	 agonist	SR	59119A	was	 shown	 to	 diminish	
spontaneous	 rhythmic	 contractile	 activity	 in	 this	 tissue	 [4].	
The	 influence	 on	 the	 contractile	 activity	 of	 another	 interesting	
β
3
-adrenoceptors	 agonist,	 BRL	 37344,	 has	 been	 studied	 in	 the	
pregnant	human	myometrium	[3,	7]. Some	reports,	 indicating	a	
marked	relaxing	effect	of	BRL	37344	on	the	nonpregnant	uterine	
smooth	muscle,	were	based	on	experiments	on	rats	and	pigs	[8,	
9].	Surprisingly,	there	is	virtually	no	information	available	on	the	
agent’s	effects	on	human	nonpregnant	uterus.		
Therefore,	taking	into	account	the	species	variability	of	β
3
-
adrenoceptor	pharmacology	investigated	[10],	the	purpose	of	the	
present	study	was	to	compare	the	ability	of	BRL	37344	to	relax	
spontaneous	contractility	of	the	human	nonpregnant	myometrium	
with	that	of	ritodrine.		
Material and methods  
Human myometrial tissue 
Human	uterine	tissues	were	collected	from	20	nonpregnant,	
premenopausal	 women	 (aged	 42-50	 years,	 median	 48	 years)	
undergoing	 hysterectomy	 for	 benign	 gynecological	 disorders,	
such	 as	 dysfunctional	 bleedings	 and	 cervical	 pre-malignancy,	
and	being	operated	upon	in	the	follicular	phase	of	their	menstrual	
cycles.	All	patients	gave	informed	consent	to	the	study	which	had	
been	approved	by	the	Ethics	Committee	of	the	Medical	University	
of	Białystok	(approval	number	R-I	–	003/307/2005).		
Myometrial	 samples	 were	 excised	 transversely	 from	
the	 uterine	 fundus,	 placed	 in	 ice-cold	 Tyrode’s	 solution,	 and	
immediately	 transferred	 to	 the	 laboratory	 where	 they	 were	
processed	 as	 previously	 described	 [6].	 Briefly,	 4-8	 strips,	 6-7	
mm	in	length	and	2x2	mm	in	cross-sectional	area	were	obtained	
under	a	dissecting	microscope.	The	strips	were	then	mounted	in	
an	organ	bath	containing	20	mL	of	Tyrode’s	solution	at	37	ºC,	pH	
7.4,	and	bubbled	with	carbogen	(95%	O
2
	+	5%	CO
2
).	Tyrode’s	
solution	consisted	of	(mmol/L):	NaCL	139.6;	KCl	2.68;	MgCl
2
 
1.05;	 NaH
2
PO
4
	 1.33;	 CaCl
2	
1.80;	 NaHCO
3
	 25.0;	 and	 glucose	
5.55.	 The	 strips	 were	 left	 in	 the	 organ	 bath	 for	 equilibration	
period	of	1-2	hours,	during	which	time	the	passive	tension	was	
adjusted	to	2	mN.	After	equilibration,	regular	phasic	contractions	
were	achieved.		
The	activity	of	the	myometrium	was	recorded	under	isometric	
conditions	by	means	of	force	transducers	with	digital	output.	BRL	
37344	or	ritodrine	was	added	cumulatively	to	the	organ	chambers	
(bath	concentrations	in	the	range	10-10	mol/L	–	10-4	mol/L	and	10-
10	mol/L	–	10-5	mol/L,	respectively)	at	15-minute	 intervals,	and	
the	effects	were	 recorded.	The	 level	of	 spontaneous	contractile	
activity	before	the	addition	of	agonist	was	regarded	as	the	control	
level.	 The	 responses	 were	 quantified	 by:	 calculating	 the	 area	
under	the	curve	(AUC)	of	active	contraction	[11],	the	amplitude,	
frequency	of	 the	contractions,	and	 the	basal	 tension.	The	AUC	
was	measured	from	basal	tension	over	a	10-minute	period	before	
a	further	addition	of	β-adrenoceptor	agonist.		
 Streszczenie  
Cel pracy: Niniejsze badanie zaprojektowano celem oceny rozkurczowego działania BRL 37344 w porównaniu do 
ritodryny (referencyjnego agonisty receptorów β
2
-adrenergicznych) na spontaniczną czynność skurczową ludzkiego 
nieciężarnego myometrium.  
Materiał i metody: Skurcz izolowanych skrawków mięśni gładkich rejestrowano w warunkach izometrycznych 
przy użyciu cyfrowych przetworników siły. Ocenie poddawano zmiany kurczliwości skrawków podczas kumulacyj-
nego zwiększania stężeń agonistów bez obecności oraz w obecności antagonistów receptorów β adrenergicznych: 
bupranololu, propranololu oraz butoksaminy.  
Wyniki: Inkubacja skrawków myometrium z BRL 37344 (10-10 – 10-4 mol/L) oraz ritodryną (10-10 – 10-5 mol/L) 
skutkowała porównywalnym (<30%) osłabieniem ich kurczliwości przejawiającym się spadkiem wartości pola po-
wierzchni pod krzywą, czyli AUC (odpowiednio, logIC
50
 -6,45 ± 0,18 oraz -8,71 ± 0,35). W odróżnieniu od ritodryny, 
której efekt działania polegał na obniżaniu średniej amplitudy skurczu, inkubacja z BRL 37344 zmniejszała średnią 
częstotliwość skurczu. Działanie rozkurczowe BRL 37344 było częściowo hamowane przez propranolol oraz bu-
pranolol, podczas gdy wpływ ritodryny był znoszony przez wszystkich zastosowanych antagonistów.  
Wnioski: Porównywalne ilościowo działanie rozkurczowe BRL 37344 oraz ritodryny na spontaniczną czynność 
skurczową ludzkiego myometrium jest wynikiem odmiennego wpływu tych agonistów na poszczególne parametry 
skurczowe. Nasze dane wskazują, iż aktywacja β3-adrenoceptorów nie jest jedynym kierunkiem działania BRL 
37344 na tę tkankę.  
 Słowa kluczowe: agoniści receptorów adrenergicznych / BRL 37344 / człowiek / 
      / myometrium / ritodryna /   
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Effect of preincubation with β-adrenoceptor antagonists
The	tissue	responses	were	evaluated	by	comparing	them	with	
those	obtained	with	the	antagonist,	before	the	administration	of	
the	first	concentration	of	BRL	37344	or	ritodrine.	Butoxamine	(β
2
-
adrenoceptor	 antagonist),	 propranolol	 (β
1
-	 and	 β
2
-adrenoceptor	
antagonist),	 and	 bupranolol	 (nonselective	 adrenoceptor	
antagonist),	each	at	concentration	of	10-6	mol/L,	were	added	to	
the	organ	bath	20	minutes	before	the	agonists	administration.		
Drugs and solutions 
BRL	37344	and	ritodrine	were	obtained	from	Sigma-Aldrich	
(St.	Louis,	MO,	USA).	Stock	solutions	of	BRL	37344	(10-2	mol/L)	
and	 ritodrine	 (10-3	mol/L)	were	prepared	daily	using	bidistilled	
water.	Series	of	dilutions	were	prepared	with	bidistilled	water	on	
the	day	of	experiment	and	were	maintained	at	room	temperature	
for	the	duration	of	the	experiment.	Propranolol	and	butoxamine	
were	 also	 from	Sigma-Aldrich.	Bupranolol	was	 obtained	 from	
Schwarz	 Pharma	 AG	 (Münchenstein,	 Switzerland).	 Stock	
solutions	 (10-3	mol/L)	of	 the	 three	antagonists	were	made	with	
bidistilled	water.	All	substances	were	added	directly	to	the	organ	
bath	containing	Tyrode’s	solution	also	made	on	daily	basis.		
Measurement of contraction parameters 
The	AUC	 parameter,	 representing	mechanical	 response	 of	
myometrial	 strips,	was	measured	by	 calculating	 the	 integral	 of	
the	 appropriate	 section	 of	 the	 curve	 [12]	 with	 the	 DASYLab	
software	unit	(version	9.0;	Laboratory	Data	Acquisition	System,	
SuperLogics,	 Waltham,	 MA,	 USA).	 Concentration–response	
curves	were	fitted	to	the	logistic	equation	by	computer	analysis	
using	 nonlinear	 regression	 (PRISM	 3.0,	 Graph	 Pad	 Software	
INC.,	San	Diego,	CA,	USA).	The	concentrations	of	agents	that	
resulted	in	half-maximal	inhibitory	effect	were	expressed	as	–log	
(IC
50
).		
Statistical analysis
All	results	are	expressed	as	means	±	SEM	and	“N”	denotes	
the	number	of	tissues	from	different	patients.	Data	were	analyzed	
statistically	with	PRISM	3	using	Student’s	 t-test	 and	a	 two-	or	
one-way	ANOVA,	where	appropriate.	The	statistical	significance	
was	considered	when	the	probability	value	(P)	was	<0.05.		
Results
All	 experiments	 were	 performed	 on	 myometrial	 strips	
exhibiting	 regular	 spontaneous	 contractile	 activity	 after	
equilibration. The	mean	 frequency	 of	 contractions	was	 3.46	 ±	
0.36	per	10-minute	interval,	the	mean	amplitude	was	3.52	±	0.29	
mN,	and	the	mean	basal	tension	was	1.69	±	0.31	mN	(N	=	52).		
Effect of BRL 37344 and ritodrine on myometrial strips 
activity
The	cumulative	addition	of	BRL	37344	or	ritodrine	resulted	
in	a	concentration-dependent	decrease	of	 the	myometrial	 strips	
activity	seen	as	a	significant	decrease	in	the	AUC	value	(Figures	
1	and	2). The	difference	of	the	IC
50
	values	for	the	two	agonists	
was	statistically	significant	(P	<	0.05;	Table	I).		
For	BRL	37344	alone	(N	=	5),	 the	 IC
50
	value	was	 -6.45	±	
0.18	and	the	mean	maximal	inhibition	was	24.94	±	1.85%	(Table	
I).	At	 the	 same	 time,	 a	 significant	 decrease	 of	 both	 the	 mean	
frequency	 of	 contractions	 and	 the	 basal	 tension	was	 observed.	
However,	BRL	37344	did	 not	 significantly	 influence	 the	mean	
amplitude	of	contractions.	(Figure	3).		
For	 ritodrine	 alone	 (N	=	13),	 the	 IC
50
	value	 and	 the	mean	
maximal	 inhibition	 were	 -8.71	 ±	 0.35	 and	 29.07	 ±	 2.24%,	
respectively.	(Table	I).	
Ritodrine caused	 a	 significant	 decrease	 of	 the	 mean	
amplitude	 of	 contractions	 and	 the	 basal	 tension.	 In	 contrast	 to	
BRL	37344,	 ritodrine	did	not	 influence	 the	mean	 frequency	of	
contractions	(Figure	3).	In	addition,	preincubation	of	myometrial	
strips	with	ritodrine	caused	a	pronounced	increase	in	the	duration	
of	contractions.	(Figure	1).		
As	 we	 have	 previously	 shown	 [6],	 preincubation	 of	
nonpregnant	 uterine	 strips	 with	 propranolol	 or	 bupranolol	
significantly	 decreases	 the	 AUC	 values	 and	 the	 amplitude	 of	
myometrial	contractions.	
Table I. Log IC50 (half-maximal inhibitory effect) and the maximal inhibition (%) of BRL 37344 and ritodrine in the absence and presence of β-adrenoceptors antagonists.  
Data are expressed as mean ±SEM.  
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Therefore,	 in	 the	 experiments	 with	 the	 antagonists,	 the	
muscular	 responses	 to	 agonists	 were	 evaluated	 by	 comparing	
them	with	 those	obtained	 in	 the	presence	of	 the	antagonist	but	
before	the	administration	of	the	first	concentration	with	agonist.		
Effect of butoxamine on the relaxation response to BRL 37344 
and ritodrine 
The	 AUC	 as	 a	 function	 of	 BRL	 37344	 concentration	
indicated	that pretreatment	with	10-6	mol/L	butoxamine	did	not	
counteract	the	BRL	37344-induced	relaxation	of	the	spontaneous	
contractions	 of	 the	 myometrial	 strips.	 A	 slight	 shift	 of	 the	
concentration-response	 curve	 was	 not	 statistically	 significant.	
(Figure	 2A	 and	Table	 I).	 The	 BRL	 37344-induced	 changes	 of	
the	 mean	 frequency	 and	 basal	 tension	 were	 not	 significantly	
influenced	by	butoxamine.	(Figures	3C	and	E).		
Preincubation	of	myometrial	strips	with	butoxamine	resulted	
in	 a	 significant	 shift	 of	 the	 concentration-response	 curve	 to	
the	 right	 for	 ritodrine.	 (Figure	2B	and	Table	 I).	There	were	no	
changes	of	the	mean	values	of	amplitude	and	frequency	after	the	
incubation	of	the	myometrium	strips	with	butoxamine.	However,	
pretreatment	with	butoxamine	abolished	the	effect of	ritodrine	on	
the	basal	tension.	(Figure	3F).		
Effect of propranolol on the relaxation response to BRL 37344 
and ritodrine 
The	addition	of	propranolol	to	the	organ	bath	before	the	first	
administration	 of	 BRL	 37344	 caused	 a	 statistically	 significant	
shift	to	the	left	of	the	concentration-effect	curve	for	BRL	37344.	
(Figure	2A	and	Table	I).	There	was	no	influence	of	propranolol	
on	 the	 decrease	 of	 the	 mean	 frequency	 of	 contractions.	 On	
the	 other	 hand,	 preincubation	 with	 propranolol	 abolished	 the	
decrease	of	the	basal	tension	caused	by	BRL	37344.	This	effect	
was	statistically	significant	 for	 the	highest	concentration	of	 the	
agonist.	(Figure	3F).		
Preincubation	of	myometrial	strips	with	propranolol	resulted	
in	 a	 significant	 rightward	 shift	 of	 the	 concentration-response	
curve	for	ritodrine.	The	range	of	ritodrine	concentrations	used	in	
our	experiments	(10-10	–	10-5	mol/L)	did	not	allow	to	fit	the	AUC	
values	to	the	logistic	equation.	(Figure	2B).	
Figure 1.  A representative recording of spontaneous contractile activity of the 
human nonpregnant myometrial strips and the effect of cumulatively 
administered: A – BRL 37344 (10-10 – 10-4  mol/L), and B – ritodrine 
(10-10 – 10-5 mol/L).   
Figure 2. Concentration-response curves for cumulatively administered: A – BRL 37344 – (10-10 – 10-4 mol/L; N = 5), and B – ritodrine –  (10-10 – 10-5 mol/L; N = 13); 
individually and after preincubation with butoxamine – , propranolol – , or bupranolol – . Spontaneous contractions of the myometrial strips before the 
addition of agonist were treated as control values. Each point represents mean ± SEM. 
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Figure 3. The cumulative effect of BRL 37344 – (N = 5) and ritodrine –  (N = 13) alone on the amplitude, frequency, and basal tension of contractions of human 
nonpregnant myometrial strips and the effects of β-adrenoceptors antagonists (each at 10-6 mol/L): butoxamine –  (N = 7 and N = 5, respectively),  
propranolol –  (N = 5 and N = 5, respectively), or bupranolol – (N = 6 and N = 6, respectively), on changes in these parameters The amplitude, frequency, 
and basal tension of spontaneous contractions before the addition of agonists were treated as control values. Each point represents mean ± SEM. 
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Pretreatment	 of	 the	 myometrial	 strips	 with	 propranolol	
abolished	 the	 concentration-dependent	 decrease	 of	 the	 mean	
amplitude	of	contractions	caused	by	ritodrine,	and	also	diminished	
the	mean	frequency	of	contractions,	but	did	not	change	the	effect	
of	ritodrine	on	the	basal	tension.	(Figure	3F).		
Effect of bupranolol on the relaxation response to BRL 37344 
and ritodrine 
The	presence	of	bupranolol	in	the	organ	bath	diminished	the	
BRL	37344-induced	relaxation	of	myometrial	strips.	This	effect	
was	 statistically	 significant	 in	 the	concentration	 range	of	10-7	–	
10-4	mol/L.	(Figure	2A	and	Table	I).	
Preincubation	 of	 the	 myometrial	 strips	 with	 bupranolol	
slightly	decreased	(P	<	0.05)	the	mean	amplitude	of	contractions	
and	markedly	abolished	(P	<	0.05)	the	influence	of	BRL	37344	
on	both	the	mean	frequency	of	contractions	and	the	basal	tension.	
(Figures	3A,	C,	and	E).  
Preincubation	of	myometrial	strips	with	bupranolol	resulted	
in	 a	 significant	 rightward	 shift	 of	 the	 concentration-response	
curve	for	ritodrine.	(Figure	2B	and	Table	I).	
In	the	concentration	range	of	10-10	–	106	mol/L	for	ritodrine,	
the	 abolition	 of	 the	 ritodrine-induced	 decrease	 of	 the	 mean	
amplitude	 of	 contractions	 was	 observed.	 In	 the	 presence	 of	
bupranolol,	only	the	highest	concentration	of	ritodrine	used	was	
able	to	cause	a	decrease	in	the	mean	frequency	of	contractions.	
Pretreatment	with	bupranolol	attenuated	the	effect	of	ritodrine	on	
the	basal	tension.	(Figure	3F).		
Discussion 
In	spite	of	a	possible	vivid	interest	in	the	topic,	only	a	few	
papers	 relative	 to	 the	 action	 of	 β
3
-adrenoceptors	 agonists	 on	
contractile	activity	of	the	human	myometrium	have	so	far	been	
published.	The	relaxation	of	human	pregnant	myometrium	by	BRL	
37344	was	first	reported	by	Dennedy	et al.	[7].	In	a	subsequent	
paper,	they	concluded	that	BRL	37344	relaxes	human	pregnant	
myometrium	 via	 β
3
-adrenoceptors	 activation	 [13].	 However,	
precise	 mechanisms	 through	 which	 uterine	 contractions	 are	
induced	and	abolished	have	not	been	fully	established	[14,	15]. 
It	 has	 been	 hypothesized	 that,	 in	 the	myometrium,	Ca2+	 influx	
through	 voltage-gated	 L-type	 channels	 is	 sufficient	 for	 normal	
spontaneous	activity	whilst	contractile	activity	evoked	by	agonists	
involves	Ca2+	release	from	the	sarcoplasmic	reticulum	[16].		
The	present	study	compared	the	influence	of	β
3
-adrenoceptor	
agonist	BRL	37344	on	 the	 contractility	of	 human	nonpregnant	
myometrium	with	the	effect	of	ritodrine	–	a	reference	compound	
as	 a	 tocolytic	 agent	 and	 a	 selective	 β
2
-adrenoceptor	 agonist.	
Interestingly,	BRL	37344	 in	a	concentration-dependent	manner	
relaxed	human	nonpregnant	myometrium.	It	is	also	of	interest	to	
compare	our	data	with	those	reported	by	Dennedy	et al. [7]	for	
the	pregnant	uterine	muscle.	Our	concentration-response	curves	
suggest	that,	with	the	maximal	inhibition	of	~25%	(IC
50
	=	-6.45	
±	0.18),	BRL	37344	is	less	efficient	in	relaxing	the	nonpregnant	
human	myometrium	than	pregnant	near-term	human	myometrium,	
where	the	maximal	inhibition	of	~62%	and	IC
50
	=	-7.26	±	0.48	
were	found	[7].	Such	an	effect	is	in	accordance	with	the	recently	
published	data	indicating	that	the	expression	of	β
3
-adrenoceptor	
mRNA	 [4],	 as	 well	 as	 the	 density	 of	 β
3
-adrenoceptor	 binding	
sites [17]	 are	 higher	 in	 pregnant	 than	 in	 nonpregnant	 human	
myometrium.	On	the	other	hand,	the	data	published	by	Doheny	
et al. [18]	 suggested	 that,	 in	 pregnant	 human	 myometrium,	
BRL	37344	attenuates	to	a	greater	degree	the	oxytocin-induced	
contractile	 activity	 than	 spontaneous	 contractile	 activity	
However,	another	β
3
-adrenoceptor	agonist,	SR	59119A,	has	been	
shown	 to	more	efficiently	decrease	 the	 spontaneous	 activity	of	
human	 pregnant	myometrium	 than	 that	 of	 human	 nonpregnant	
myometrium	[4],	data	in	support	of	our	conclusion.		
The	position	of	the	concentration-response	curve	for	ritodrine	
to	the	left	of	the	curve	for	BRL	37344	indicates	its	higher	potency.	
Although	 there	was	no	statistically	significant	difference	 in	 the	
maximal	 inhibition	values,	BRL	37344	seems	to	be	 less	potent	
than	ritodrine	in	relaxing	nonpregnant	myometrium.	The	analysis	
of	amplitude,	frequency	and	basal	tension	revealed	the	differences	
in	the	mechanisms	of	relaxation	caused	by	the	two	β-adrenoceptor	
agonists.	A	concentration-dependent	decrease	of	 the	amplitude,	
but	not	the	frequency	of	contractions,	was	characteristic	for	the	
ritodrine-induced	relaxation.	BRL	37344,	however,	decreased	the	
frequency	of	contractions	without	changing	their	amplitude.	Both	
compounds	 diminished	 the	 basal	 tension	 of	 the	 myometrium	
strips.		
The	 blockage	 of	 β
2
-adrenoceptors	 with	 10-6	 mol/L	
butoxamine	considerably	inhibited	the	relaxing	effect	of	ritodrine,	
mainly	by	preventing	the	decrease	of	basal	tension.	Surprisingly,	
butoxamine	did	not	change	 the	effect	of	 ritodrine	on	 the	mean	
amplitude	of	contractions.	Nevertheless,	the	effects	exerted	by	the	
β-adrenoceptor	agonists	on	the	strips	incubated	with	butoxamine	
indicate	that	the	effect	of	BRL	37344	on	the	human	nonpregnant	
myometrium	is	not	mediated	by	β
2
-adrenoceptors.		
Bupranolol,	 the	 non-specific	 β-adrenoceptors	 antagonist,	
at	 concentration	 10-6	 mol/L,	 decreased	 the	 responses	 of	 the	
myometrium	 strips	 to	 both	 ritodrine	 and	 BRL	 37344.	At	 high	
concentrations	 bupranolol	 antagonizes	 both	 the	 β
2
-	 and	 β
3
-
adrenoceptors.	 Thus,	 our	 results	 support	 the	 view	 that	 the	
relaxation	of	human	nonpregnant	myometrium	by	BRL	37344	is	
mediated	by	β
3
-adrenoceptors.		
Preincubation	of	the	strips	with	propranolol	counteracted	the	
relaxation	induced	by	ritodrine	and	caused	a	paradoxical	leftward	
shift	 of	 the	 concentration-response	 curve	 for	 BRL	 37344.	We	
cannot	 at	 the	 moment	 provide	 any	 concrete	 explanation	 for	
the	 above-mentioned	 shift.	 However,	 it	 has	 been	 reported	 that	
propranolol,	 BRL	 37344,	 and	 bupranolol	 demonstrate	 affinity	
to	 α-adrenergic	 receptors	 [19,	 20]. The	 binding	 of	 propranolol	
to	 α-adrenergic	 receptors	 might	 result	 in	 an	 apparent	 increase	
in	 potency	 of	 the	 β
3
-adrenoceptor	 agonist.	 It	 has	 also	 been	
reported	 that	 β-adrenoceptor	 antagonists	 induce	 changes	 in	 the	
electrophysiological	 properties	 of	 myocardial	 cell	 membranes,	
such	as	automaticity,	excitability,	conductivity,	and	refractoriness	
[21].		
The	 analysis	 of	 the	 β-adrenoceptor	 agonists	 action	 on	 the	
parameters	of	contractile	activity	shows	that,	in	the	presence	of	
propranolol,	BRL	37344	causes	a	decrease	of	 the	amplitude	of	
the	contractions	but	no	change	in	their	frequency	or	basal	tension.	
This	finding	implies	the	existence	of	a	second	mechanism	of	BRL	
37344	action	on	the	human	nonpregnant	myometrium,	which	is	
not	related	to	the	activation	of	the	β
3
-adrenoceptors.		
From	 the	 clinical	 standpoint,	 women	 with	 primary	
dysmenorrhea	 have	 been	 shown	 to	 experience	 immediate	 pain	
relief	following	β
2
-adrenoceptor	agonist	terbutaline	administration	
[22,	23].	A	decrease	in	the	myometrial	hyperactivity	(represented	
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by	contractions	of	high	amplitude	and	 long	duration)	has	been	
found	 as	 the	 treatment’s	 mechanism	 [22],	 and	 various	 routes	
of	 administration	 have	 been	 tested	 [23,	 24].	Thus,	 insight	 into	
detailed	means	 of	 action	 of	 particular	 β-adrenoceptor	 agonists	
in	 nonpregnant	 uterus	 could	 help	 design	 appropriate	 causative	
treatment	for	primary	dysmenorrhea	with	minimal	side	effects.		
Concisely,	 our	 results	 support	 the	 view	 that	 relaxation	 of	
human	 nonpregnant	 myometrium	 by	 BRL	 37344	 is	 mediated	
through	 β
3
-adrenoceptors.	A	 comparison	 of	 the	 effects	 of	BRL	
37344	 and	 ritodrine	 shows	 that	 both	 β-adrenoceptors	 agonists	
are	 effective	 in	 relaxing	nonpregnant	myometrium,	while	BRL	
37344	seems	less	potent	 than	ritodrine.	The	present	data	 imply	
the	existence	of	 a	 second	mechanism	of	BRL	37344	action	on	
the	human	nonpregnant	myometrium,	which	is	not	related	to	the	
activation	of	the	β
3
-adrenoceptors.		
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